Transverse Myelitis autoimmune spinal cord disease

RESULTS: Objective neurological findings improved in 89%
of the PE group and 90% of the PE+IVIG/CS group, compared
with only 72% of the CS and 60% of the IVIG groups. Improvement
determined by laboratory tests was seen in 57% of the PE and 57% of
the PE+IVIG/CS groups, compared with only 15% of the CS and none of
the IVIG groups. Thus, the improvement rate determined by laboratory
tests was significantly greater for therapies including PE than for
those without PE (p=0.0187). CONCLUSIONS: These data suggest that
immunotherapy is effective in myelitis with atopic diathesis despite
a chronic persistent course, and that PE is the most beneficial
immunotherapy. This last study shows that plasmapheresis and IVIg
combination is very effective for treatment of Myelitis
(inflammation of spinal cord). Improvement seen in 90% of the group.
If you cannot get IVIg use Omega-3 fatty acids, use Vitamin-D and
hydrogen peroxide read our diet chapter. Great benefit will be seen
from electronic stimulation.
J
Neurol Sci. 2004 Dec 15;227(1):39-47.
Effect of immunotherapy in myelitis with atopic
diathesis.
Murai H, Arahata H, Osoegawa M, Ochi H, Minohara M, Taniwaki T,
Tobimatsu S, Mihara F, Tsuruta Y, Inaba S, Kira J.
Department of Neurology, Neurological Institute, Graduate School of
Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
OBJECTIVE: A recent nationwide survey of myelitis with atopic
diathesis in Japan disclosed that the disease frequently shows a
chronic persistent course. A neuropathological study of the spinal
cord also revealed chronic active inflammation. Since the effects of
various immunotherapies have not been studied extensively in this
condition, we evaluated the efficacies of various immunotherapies in
patients with myelitis with atopic diathesis. PATIENTS AND METHODS:
Forty-two treatments in 26 patients with myelitis with atopic
diathesis were retrospectively analyzed. One of the following
therapies was administered: (1) corticosteroids (CS) (pulse therapy
followed by oral administration with gradual tapering); (2)
intravenous immunoglobulin (IVIG) (400 mg/kg/day for 5 consecutive
days); (3) plasma exchanges (PE); or (4) PE followed by IVIG or CS (PE+IVIG/CS).
The therapeutic efficacies were evaluated by thorough neurological
examination and laboratory tests including MRI, somatosensory evoked
potentials (SEPs) and motor evoked potentials (MEPs).
PMID: 15546590 [PubMed - indexed for MEDLINE]
in the central nervous system